DCVMN Training Workshop- Vaccine Safety and Pharmacovigilance Strategies

Documents

• 2017_rodewald_-_beijing_dcvmn_-_it_takes_a_program_to_vaccinate_safely_and_e (...) (PDF - 7 Mb)
• beijing_workshop_agenda_final_1.pdf (PDF - 205 kb)
• cioms_blank_form.pdf (PDF - 76.5 kb)
• e1_1_illustrate_importance_of_pv.pdf (PDF - 148.1 kb)
• e1_2_practical_exercies_basic_pv.pdf (PDF - 151.2 kb)
• exercise_2.2_instructions.pdf (PDF - 43.5 kb)
• l1_1_importance_of_pv.pdf (PDF - 155.2 kb)
• l1_2_legal_framework.pdf (PDF - 865.5 kb)
• l1_3_specifics_of_vaccine_pv.pdf (PDF - 1.5 Mb)
• l1_4_basic_elements_pv_system.pdf (PDF - 376 kb)
• l2_1_eu_and_us_specific_requirements.pdf (PDF - 249.8 kb)
• l2_2_principles_clinical_safety.pdf (PDF - 584.9 kb)
• l2_3_post_marketing_pv_part_1.pdf (PDF - 226.9 kb)
• l3_1_active_pharmacovigilance.pdf (PDF - 1.2 Mb)
• l3_2_signal_detection.pdf (PDF - 669.6 kb)
• l3_3_pm_aggregate_reporting_psur_.pdf (PDF - 680.5 kb)
• l4_1_practical_considerations.pdf (PDF - 231 kb)
• l4_2_quality_management.pdf (PDF - 388.8 kb)
• l4_3_dsurs.pdf (PDF - 191.5 kb)
• l4_4monitoring_literature.pdf (PDF - 182.6 kb)
• munters_humidity_control_vs_microorganisms_april_2017.pdf (PDF - 14.3 Mb)
• path_introduction20170429.pdf (PDF - 3.4 Mb)
• set_of_individual_safety_report.pdf (PDF - 53.9 kb)